Menu
The educational series will bring together leading 3D-Printing experts from around the globe to discuss technological advancements in process, equipment, systems, product applications, and manufacturing capabilities
WEST LAFAYETTE, Ind. and ROCKVILLE, Md., Aug. 4, 2021 /PRNewswire/ -- Purdue University, in partnership with US Pharmacopeia and sponsorship from Aprecia Pharmaceuticals, LLC, announced a new pharmaceutical industry technology forum focused on 3D-Printing pharmaceutical medications and the benefits to patients, pharmaceutical executives, formulation scientists, and compounding pharmacists. The forum will begin with a one-hour introduction session on September 14, 2021 and will continue monthly into 2022.
Building on the USP and International Association for Pharmaceutical Technology (APV) sponsored week-long event held in July 2020, titled "Quality of 3D Printing of Medicines and Supplements," this event will explore the use of various 3DP technologies to support new indications, improved formulations, or create new delivery systems. The series will provide examples—including case studies for pharmaceutical executives—on how 3DP manufacturing can accelerate clinical development, enhance the innovation value of novel molecules, and extend the life cycle of approved products.
"Purdue is committed to the advancement of technologies such as 3DP for pharmaceutical development that can bring patient centric products to market," said Eric L. Barker, PhD, Dean of the Purdue College of Pharmacy. "Simultaneously, Purdue continues to offer its students, faculty, alumni, and industry colleagues access to educational materials that bring awareness to such technological advancements."
"USP is excited to partner with Purdue University and Aprecia in leading the conversation on standards in ensuring quality in 3DP. Robust engagement with the 3DP community enables USP to learn from, adapt, and educate stakeholders in an agile manner to meet their needs and reduce barriers to innovation in manufacturing and emerging technologies such as 3DP," said Ronald T. Piervincenzi, Ph.D., CEO of USP.
As the global leader in 3DP for pharmaceutical manufacturing, Aprecia is the first and only company to gain FDA regulatory approval and to launch a 3D-Printed product, Spritam, into the market. Since launching Spritam in 2015, Aprecia has continued to advance a pipeline of market differentiated products and state-of-the-art equipment.
"Aprecia continues to focus its passion on innovation and helping its pharma partners bring to market differentiated products that improve patient and caregiver lives," said Chris Gilmore, CEO of Aprecia. "We are excited to partner with these visionary organizations in bringing this needed content and discussion to the pharmaceutical industry."
Click here to register for the forum
About Purdue University
Purdue University, a top public research institution, offers higher education at its highest proven value. Committed to affordability, the university has frozen tuition and most fees since 2012. Committed to student success, Purdue is changing the student experience with greater focus on faculty-student interaction and creative use of technology. Committed to pursuing scientific discoveries and engineered solutions, Purdue has streamlined pathways for faculty and student innovators who have a vision for moving the world forward.
About USP
USP is an independent, nonprofit, scientific organization that sets quality standards for medicines, dietary supplements, and food ingredients worldwide. USP's quality standards are enforceable in the United States by the Food and Drug Administration and legally recognized in more than 50 countries. These standards, which are continuously developed and revised by more than 750 volunteer experts in science, industry, healthcare, and academia, are also used in more than 150 countries. Learn more at www.usp.org.
About Aprecia
Founded in 2004, Aprecia received the first and only FDA approved three-dimensionally-printed (3DP) pharmaceutical product approval in 2015. Aprecia uses its ZipDose® Technology to create rapidly disintegrating oral dosage forms that are easy to take and easy to administer. Without compression during the 3DP manufacturing process, engineered and coated particles such as taste masking and modified release are possible on large dose products (over a 1000mg). Aprecia directly owns a patent estate for novel 3DP machines and pharmaceutical 3DP applications. It licenses its exclusive technology platform to pharmaceutical partners to extend product lines, improve patient reach and experience, and address FDA requirements as a pediatric delivery form. For more information, visit www.aprecia.com.
